These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8268880)

  • 1. Cost-effectiveness of the treatment of hypertension.
    Bulpitt CJ; Fletcher AE
    Clin Exp Hypertens; 1993 Nov; 15(6):1131-46. PubMed ID: 8268880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal.
    Kawachi I; Malcolm LA
    J Hypertens; 1991 Mar; 9(3):199-208. PubMed ID: 1851782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
    Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension.
    Chung O; Vongpatanasin W; Bonaventura K; Lotan Y; Sohns C; Haverkamp W; Dorenkamp M
    J Hypertens; 2014 Dec; 32(12):2411-21; discussion 2421. PubMed ID: 25255395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?
    Mullins CD; Blak BT; Akhras KS
    Value Health; 2002; 5(4):359-71. PubMed ID: 12102698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of hypertension treatment.
    Ménard J
    Clin Exp Hypertens; 1996; 18(3-4):399-413. PubMed ID: 8743030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
    Plans-Rubió P
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?
    Mar J; Rodríguez-Artalejo F
    J Hypertens; 2001 Jan; 19(1):149-55. PubMed ID: 11204296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive treatment in the elderly.
    Lindholm LH
    Clin Exp Hypertens; 1996; 18(3-4):435-47. PubMed ID: 8743033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
    Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.